Therapeutic implications of cancer-associated fibroblast heterogeneity: insights from single-cell and multi-omics analysis
This study offers a comprehensive analysis of CAF heterogeneity and its impact on TME, patient prognosis, and drug sensitivity. The developed RiskScore model provides theoretical support for personalized treatment based on CAF-related genes, offering new insights into CAF-driven tumor progression and potential targets for precision oncology and immunotherapy.
Authors
- Yi Ding (ORCID: https://orcid.org/0000-0002-1958-8524)
- HaoLin Liu
- Runan Dong
- Zhongyou Xia (ORCID: https://orcid.org/0000-0003-3205-4903)
- Shicheng Fan (ORCID: https://orcid.org/0000-0003-3236-3765)
- Xiaodong Liu (ORCID: https://orcid.org/0000-0002-5915-4499)
- Juan Qin (ORCID: https://orcid.org/0000-0002-0821-6290)
- Liang Peng (ORCID: https://orcid.org/0000-0001-7021-4651)
- Yumin Wang (ORCID: https://orcid.org/0000-0001-8243-3659)
- Peng Gu (ORCID: https://orcid.org/0000-0002-9646-172X)
- Guoqiang Liao
- Junxiong Li (ORCID: https://orcid.org/0000-0002-1951-2589)
Institutions
- Sichuan University (CN)
- Kunming Medical University (CN)
- Wenzhou Medical University (CN)
- West China Hospital of Sichuan University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
- Nanchong Central Hospital (CN)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1580315
- Citations
- 1
- Primary Topic
- Cancer Cells and Metastasis
- Type
- article
- Field-Weighted Citation Impact
- 1.05